prostate-report.org

Two recent studies suggest value of intermittent hormone therapy

Two European studies that have just been published appear to validate the long-term concept of intermittent hormone therapy (IHT).

The first study was designed to determine whether intermittent therapy is associated with a shorter time to progression

The authors of this study concluded that, “IHT should be considered for use in routine practice because it is associated with no reduction in survival, no clinically meaningful impairment in QoL, better sexual activity, and considerable economic benefit to the individual and the community.”

The second study presents data from a single-center study of  intermittent androgen deprivation carried out between 1992 and 2008.

In this study the authors conclude that intermittent hormone therapy “is an acceptable treatment in different stages of [prostate cancer]. Duration of cycle decreased progressively during therapy. Age, Gleason score and PSA are factors predicting mortality.”